[INSTITUTION LOGO]

RESEARCH PROTOCOL

Protocol: Circadian-Entrained Schwann Cell Exosome Therapy for Axonal Protection in CIDP via BMAL1-Stabilized Neurotrophic Cargo

Protocol Number:	[AUTO-GENERATED]
Version:	2.0
Version Date:	December 07, 2025
Study Phase:	Preclinical
SPIRIT Compliance:	87%

CONFIDENTIAL

This document contains confidential information. Do not distribute without authorization.

PROTOCOL SYNOPSIS

Protocol Title	Protocol: Circadian-Entrained Schwann Cell Exosome Therapy for Axonal Protection in CIDP via BMAL1-Stabilized Neurotrophic Cargo
Short Title	Protocol: Circadian-Entrained Schwann Cell Exosome
Study Phase	Preclinical
Study Type	Basic Science
Primary Objective	To evaluate the effect of circadian-entrained Schwann cell exosome therapy on axonal degeneration score in a CIDP animal model at 6 months post-treatment initiation
Study Design	Preclinical In-Vivo
Study Population	Xenograft model using humanized peripheral nerve tissue implanted in immunodeficient mice (e.g., NSG mice) with induced CIDP-like pathology. Animals will be 8-10 week old male and female mice, housed in circadian-controlled conditions (12:12 light-dark cycle). CIDP pathology will be induced through passive transfer of anti-ganglioside antibodies or inflammatory cytokine administration to mimic human disease mechanisms.
Sample Size	To be calculated
Number of Arms	2
Treatment Duration	6 months
Primary Endpoint	To evaluate the effect of circadian-entrained Schwann cell exosome therapy on axonal degeneration score in a CIDP animal model at 6 months post-treatment initiation
Statistical Analysis	Mixed-effects model for repeated measures (MMRM)
Estimated Duration	15.5 months
Budget Estimate	N/A
Study Setting	Animal facility with circadian-controlled environment and molecular biology lab

TABLE OF CONTENTS

1. ADMINISTRATIVE INFORMATION

1.1 Protocol Identification

1.2 Sponsor and Investigator Information

1.3 Roles and Responsibilities

2. INTRODUCTION

2.1 Background and Rationale

2.2 Research Question and Objectives

3. METHODS: PARTICIPANTS

3.1 Trial Design

3.2 Study Setting

3.3 Eligibility Criteria

3.4 Recruitment

4. METHODS: INTERVENTIONS

4.1 Intervention Description

4.2 Intervention Modifications

4.3 Adherence Monitoring

5. METHODS: OUTCOMES

5.1 Primary Outcome

5.2 Secondary Outcomes

5.3 Outcome Assessment

6. METHODS: SAMPLE SIZE

7. METHODS: ASSIGNMENT OF INTERVENTIONS

7.1 Randomization

7.2 Blinding

8. METHODS: DATA COLLECTION AND MANAGEMENT

8.1 Data Collection Methods

8.2 Data Management

8.3 Retention Strategies

9. METHODS: STATISTICAL ANALYSIS

9.1 Analysis Populations

9.2 Statistical Methods

9.3 Interim Analyses

10. METHODS: MONITORING

10.1 Data Monitoring Committee

10.2 Adverse Events

10.3 Auditing

11. ETHICS AND DISSEMINATION

11.1 Research Ethics Approval

11.2 Protocol Amendments

11.3 Consent

11.4 Confidentiality

11.5 Dissemination Policy

12. APPENDICES

A. SPIRIT Checklist

B. Schedule of Assessments

C. Informed Consent Template

D. Case Report Forms

[Update Table of Contents in Word: References → Update Table]

ABBREVIATIONS AND DEFINITIONS

Abbreviation	Definition
AE	Adverse Event
ANOVA	Analysis of Variance
CI	Confidence Interval
CRF	Case Report Form
DMC	Data Monitoring Committee
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
IACUC	Institutional Animal Care and Use Committee
ICH	International Council for Harmonisation
IRB	Institutional Review Board
ITT	Intention-to-Treat
N/A	Not Applicable
PI	Principal Investigator
PP	Per Protocol
QC	Quality Control
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SD	Standard Deviation
SEM	Standard Error of the Mean
SOP	Standard Operating Procedure
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials

1. ADMINISTRATIVE INFORMATION

1.1 Protocol Identification

Full Protocol Title:	Protocol: Circadian-Entrained Schwann Cell Exosome Therapy for Axonal Protection in CIDP via BMAL1-Stabilized Neurotrophic Cargo
Short Title:	[SHORT TITLE]
Protocol Number:	[PROTOCOL-XXX]
Protocol Version:	2.0
Protocol Date:	December 07, 2025
Trial Registration:	[To be registered at ClinicalTrials.gov/IACUC]

1.2 Sponsor and Investigator Information

1.2.1 Principal Investigator

Name:	[PI NAME, DEGREE]
Title:	[PI TITLE]
Institution:	[INSTITUTION NAME]
Address:	[FULL ADDRESS]
Email/Phone:	[EMAIL] / [PHONE]

1.2.2 Funding Source

[FUNDING SOURCE - Grant number, sponsor name]

1.3 Roles and Responsibilities

The Principal Investigator is responsible for the overall conduct of the study, including protocol compliance, data integrity, and safety reporting. All study personnel will be trained on GCP/GLP requirements and study-specific procedures.

1.3.1 Study Committees

• Trial Steering Committee: [To be formed if required]

• Data Monitoring Committee: [To be formed for studies with interim analyses]

• Safety Review Board: [As required by IACUC/IRB]

2. INTRODUCTION

2.1 Background and Rationale

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder characterized by progressive peripheral nerve damage, leading to significant disability. Current standard treatments primarily focus on immunomodulation through intravenous immunoglobulin (IVIG), corticosteroids, or plasma exchange. While these approaches can reduce inflammation and slow disease progression, they fail to address the underlying axonal degeneration that drives long-term disability. Immunomodulatory therapies do not directly protect axons from oxidative stress, mitochondrial dysfunction, or neurofilament destabilization, leaving patients vulnerable to irreversible nerve damage. There is a critical unmet need for neuroprotective strategies that target the root causes of axonal degeneration in CIDP, particularly those that restore Schwann cell support functions and circadian-regulated maintenance pathways.

Schwann cells play essential roles in peripheral nerve homeostasis, including neurotrophic factor secretion, metabolic support, and myelin maintenance. In CIDP, Schwann cell dysfunction contributes to axonal vulnerability. Circadian rhythms regulate numerous cellular processes in the nervous system, including mitochondrial function, antioxidant responses, and cytoskeletal stability. The circadian transcription factor BMAL1 coordinates these protective pathways, but its dysregulation in neuroinflammatory conditions may exacerbate axonal damage. Exosome-based delivery offers a promising approach for targeted therapy, as Schwann cell-derived exosomes can be engineered to carry neuroprotective cargo and specifically bind to peripheral axons via surface markers like L1CAM. This protocol proposes a novel therapeutic strategy that combines circadian biology with exosome technology to address the fundamental limitations of current CIDP treatments.

2.1.1 Current State of Knowledge

[Describe current understanding of the disease/condition and existing treatments]

2.1.2 Knowledge Gap

[Identify specific gaps in current knowledge that this study addresses]

2.2 Research Question and Objectives

2.2.1 Research Hypothesis

Engineered Schwann cell-derived exosomes containing BMAL1-stabilized neurotrophic factors (BDNF, NGF, GDNF) and circadian regulatory molecules will reduce axonal degeneration in a CIDP model by enhancing mitochondrial function (via PGC-1α), reducing oxidative stress (via NRF2), and stabilizing neurofilaments, leading to improved electrophysiological and functional outcomes compared to vehicle control.

2.2.2 Primary Objective

To evaluate the effect of circadian-entrained Schwann cell exosome therapy on axonal degeneration score in a CIDP animal model at 6 months post-treatment initiation

2.2.3 Secondary Objectives

1. To assess changes in electrophysiological parameters (CMAP amplitude) at 6 months
2. To measure functional improvement using a validated neuropathy scale at 12 months

3. METHODS: PARTICIPANTS

3.1 Trial Design

This is a Preclinical In-Vivo study. Study type: Basic Science. Phase: Preclinical.

[INSERT STUDY DESIGN SCHEMA/FLOWCHART HERE]

3.2 Study Setting

Study Setting: Animal facility with circadian-controlled environment and molecular biology lab

3.3 Eligibility Criteria

3.3.1 Inclusion Criteria

1. Age 8-10 weeks
2. Confirmed successful xenograft engraftment
3. Baseline electrophysiological evidence of neuropathy
4. Body weight within 20% of strain average

3.3.2 Exclusion Criteria

1. Pre-existing neurological conditions
2. Failed xenograft integration
3. Severe systemic illness
4. Abnormal circadian rhythm patterns at baseline

3.4 Recruitment

[Describe recruitment strategies and timeline]

4. METHODS: INTERVENTIONS

4.1 Intervention Description

4.1.1 Experimental

Intervention:	Engineered Schwann cell-derived exosomes containing BMAL1-stabilized neurotrophic factors (BDNF, NGF, GDNF), circadian regulatory molecules, and surface-modified with L1CAM for targeted axonal delivery. Exosomes will be purified from genetically modified Schwann cells overexpressing BMAL1 and neurotrophic factors, with HSP90 stabilization of cargo.
Dosage:	100.0 µg exosomes per injection (literature-validated dose)
Route of Administration:	N/A
Frequency:	Twice weekly (BIW)
Duration:	6 months
Target N:	20
Dose Justification:	See Section 4.1.X

4.1.2 Control

Intervention:	Vehicle control (phosphate-buffered saline with equivalent exosome purification buffer components)
Dosage:	Equivalent volume to experimental dose
Route of Administration:	N/A
Frequency:	Twice weekly (BIW)
Duration:	6 months
Target N:	20
Dose Justification:	See Section 4.1.X

4.1.X Dose Justification

Recommended dose: 5.0 mg/kg. Based on 6 literature sources. Dose range in literature: 2.5-5.0.

4.2 Intervention Modifications

[Describe criteria and procedures for modifying or discontinuing interventions]

4.3 Adherence and Concomitant Care

4.3.1 Adherence Monitoring

[Describe strategies to monitor/improve adherence]

4.3.2 Permitted Concomitant Care

[List permitted and prohibited concomitant interventions]

4.3.3 Post-Trial Care

[Describe post-trial access to intervention if applicable]

5. METHODS: OUTCOMES

5.1 Primary Outcome

Primary Endpoint:	To evaluate the effect of circadian-entrained Schwann cell exosome therapy on axonal degeneration score in a CIDP animal model at 6 months post-treatment initiation
Measurement Method:	[METHOD OF MEASUREMENT]
Assessment Timepoints:	[TIMEPOINTS]
Clinically Significant Difference:	[MCID IF APPLICABLE]

5.2 Secondary Outcomes

1. BMAL1 expression level (Western blot, normalized to loading control)
2. BDNF expression level (Western blot, normalized to loading control)
3. Body weight change from baseline (%)
4. Target engagement biomarker levels
5. Adverse events and mortality during study period

6. METHODS: SAMPLE SIZE

Total Sample Size:	20
Sample Per Group:	10
Effect Size:	[d = X.XX]
Alpha (Type I Error):	0.05
Power (1-β):	0.80
Statistical Test:	[TEST TYPE]
Attrition Rate:	10%
Effect Size Source:	default

[PROVIDE DETAILED SAMPLE SIZE JUSTIFICATION]

7. METHODS: ASSIGNMENT OF INTERVENTIONS

7.1 Randomization

7.1.1 Sequence Generation

Randomization Method: Block randomization stratified by sex and baseline neuropathy severity

7.1.2 Allocation Concealment

Allocation Concealment: Sequentially numbered, opaque, sealed envelopes prepared by statistician not involved in treatment administration

7.1.3 Implementation

[Describe who generates allocation sequence, enrolls participants, assigns interventions]

7.2 Blinding

7.2.1 Blinding Procedures

Blinding Level: Double-blind
Details: Investigators performing assessments and data analysis are blinded to treatment allocation. Treatment solutions are prepared and coded by separate personnel not involved in outcome measurement.

7.2.2 Emergency Unblinding

[Describe circumstances and procedures for emergency unblinding]

8. METHODS: DATA COLLECTION AND MANAGEMENT

8.1 Data Collection Methods

Data Collection: Electronic lab notebook with integrated data capture forms, validated for 21 CFR Part 11 compliance

8.1.1 Schedule of Assessments

Assessment	Baseline	Month 3	Month 6
Axonal degeneration scoring			X
Behavioral assessment	X	X	X
Blood collection for inflammatory markers	X		
Body weight	X	X	X
Electrophysiology (CMAP)	X	X	X
Euthanasia and comprehensive tissue collection			X
Interim tissue biopsy for molecular analysis		X	
Molecular pathway analysis			X

8.2 Data Management

Quality Control: Daily calibration of electrophysiology equipment, blinded duplicate scoring of histological samples, periodic audit of data entry by independent quality assurance personnel

8.2.1 Data Entry and Validation

- All continuous variables must be within 3 standard deviations of group mean
- Missing data >10% triggers protocol deviation report
- Outcome assessor agreement must be ≥90% for subjective measures

8.3 Participant/Subject Retention

[Describe strategies to minimize loss to follow-up]

9. METHODS: STATISTICAL ANALYSIS

9.1 Analysis Populations

• Intention-to-Treat (ITT): All subjects randomized, analyzed as assigned
• Per-Protocol (PP): Subjects completing study without major protocol deviations
• Safety Population: All subjects receiving at least one dose of intervention

9.2 Statistical Methods for Primary Outcome

Primary Analysis Method: Mixed-effects model for repeated measures (MMRM)
Primary Endpoint: To evaluate the effect of circadian-entrained Schwann cell exosome therapy on axonal degeneration score in a CIDP animal model at 6 months post-treatment initiation
Alpha Level: 0.05
Multiple Comparison Adjustment: [IF APPLICABLE]

9.3 Subgroup and Exploratory Analyses

[DESCRIBE PRE-SPECIFIED SUBGROUP ANALYSES]

9.4 Handling of Missing Data

Mixed-effects model uses all available data (MAR assumption); sensitivity with pattern-mixture models

9.5 Interim Analyses

[DESCRIBE INTERIM ANALYSIS PLAN IF APPLICABLE - including stopping rules]

10. METHODS: MONITORING

10.1 Data Monitoring Committee

[Describe composition, role, and procedures of DMC, including frequency of meetings and criteria for study termination]

10.2 Adverse Events and Harms

10.2.1 Definitions

Adverse Event (AE): Any untoward occurrence during the study, whether or not related to the intervention.
Serious Adverse Event (SAE): Death, life-threatening, hospitalization, disability, congenital anomaly, or other medically significant event.

10.2.2 Recording and Reporting

[Describe procedures for recording and reporting AEs/SAEs]

10.2.3 Risk Register

Risk	Likelihood	Severity	Mitigation
Exosome-induced immune response or toxicity in animal models	Medium	High	Conduct dose-escalation studies with comprehensive histopathological analysis; use purified exosomes from validated sources; include control groups receiving vehicle or sham treatment
Inconsistent exosome production or cargo stability affecting reproducibility	High	Medium	Implement standardized protocols for Schwann cell culture, exosome isolation, and BMAL1 stabilization; perform quality control assays (e.g., nanoparticle tracking, Western blot for neurotrophic factors) before each administration
Unintended off-target effects of BMAL1 stabilization on circadian rhythms	Low	Medium	Include behavioral monitoring for circadian disruptions (e.g., activity patterns); use tissue-specific exosome

			targeting strategies; limit study duration to minimize chronic effects
Ethical concerns regarding animal welfare in chronic inflammatory models	Medium	High	Adhere to 3Rs principles (Replacement, Reduction, Refinement); use humane endpoints with predefined clinical scores; provide analgesia and supportive care as per veterinary guidelines

10.2.4 Stopping Rules

Unexpected mortality rate exceeding 20% in any treatment groupSevere adverse events (e.g., paralysis, seizures) in more than 30% of animals receiving therapyEvidence of systemic toxicity (e.g., organ failure) confirmed by histopathology

10.3 Auditing

[Describe plans for auditing trial conduct, including frequency and independence of auditing]

11. ETHICS AND DISSEMINATION

11.1 Research Ethics Approval

Ethical Considerations: IACUC approval required prior to initiation, adherence to ARRIVE 2.0 guidelines for preclinical research, minimization of animal discomfort through appropriate analgesia and humane endpoints

Regulatory Compliance: ['GLP compliance for all procedures', 'FDA requirements for exosome-based therapeutic development', 'Biosafety level 2 containment for xenograft procedures']

This protocol will be submitted for approval to [IACUC/IRB NAME] prior to study initiation. The study will be conducted in accordance with applicable regulations and guidelines including [GLP/GCP/ARRIVE guidelines as applicable].

11.2 Protocol Amendments

Any modifications to the protocol that may affect study conduct, participant safety, or data integrity will be documented as protocol amendments. Amendments will be submitted for approval before implementation.

Amendment #	Date	Description	Approval Date
[Future amendments]			

11.3 Consent

[For clinical studies: Describe informed consent process]
[For preclinical: Not applicable - IACUC approval covers animal use]

11.4 Confidentiality

All study data will be handled in accordance with applicable privacy regulations. Data will be de-identified where possible. Access to identifiable data will be restricted to authorized personnel only.

11.5 Declaration of Interests

[All investigators will declare any conflicts of interest]

11.6 Access to Data

[Describe who will have access to final trial dataset]

11.7 Post-Trial Care

[Describe provisions for post-trial care if applicable]

11.8 Dissemination Policy

11.8.1 Publication Plan

Target journal: Brain or Journal of Clinical Investigation; Submission timeline: 3 months after study completion

11.8.2 Authorship

Authorship will be determined according to ICMJE guidelines. All contributors meeting authorship criteria will be included.

11.8.3 Data Sharing

De-identified data will be deposited in Figshare or similar repository upon publication, with materials available through MTA for academic researchers

12. APPENDICES

Appendix A: SPIRIT 2013 Checklist

[See next section for completed SPIRIT checklist]

Appendix B: Schedule of Assessments

[Detailed Schedule of Assessments - see Section 8.1.1]

Appendix C: Informed Consent Template

[ATTACH INFORMED CONSENT FORM IF APPLICABLE]

Appendix D: Case Report Forms

[ATTACH SAMPLE CRFs]

Appendix E: Biological Specimens

[Describe plans for collection, storage, and future use of biological specimens]

REFERENCES

Evidence Summary: 353 evidence sources analyzed

Evidence Traceability:

• MECHANISM_OF_ACTION: 28468935, 35682615, 15272267

• MOLECULAR_TARGETS: 15272267

• SAFETY_PROFILE: 28889275, 40344319, 37015772

[INSERT FULL REFERENCE LIST IN VANCOUVER OR APA FORMAT]

SPIRIT 2013 CHECKLIST

This protocol was prepared according to SPIRIT 2013 guidelines (Standard Protocol Items: Recommendations for Interventional Trials).
Reference: Chan AW, et al. Ann Intern Med. 2013;158:200-7.

Item #	Description	Addressed	Page/Section
1	Protocol title	✓	[Section]
2a	Trial registration	✓	[Section]
2b	Protocol version	✓	[Section]
3	Funding sources	✓	[Section]
4a	Principal investigator	✓	[Section]
4b	Sponsor contact	✓	[Section]
5a	Sponsor/collaborator roles	✓	[Section]
5b	Trial steering committee	✓	[Section]
5c	Data management committee	✓	[Section]
5d	Coordinating centre	✓	[Section]
6a	Background/rationale	✓	[Section]
6b	Specific objectives/hypotheses	✓	[Section]
7	Trial design	✓	[Section]
8	Study setting	✓	[Section]
9	Eligibility criteria	✓	[Section]
10	Interventions	✓	[Section]
11a	Intervention modifications	✓	[Section]
11b	Intervention adherence	✓	[Section]
11c	Concomitant care	✓	[Section]
11d	Post-trial care	✓	[Section]
12	Primary outcome	✓	[Section]
13	Secondary outcomes	✓	[Section]
14	Sample size	✓	[Section]
15	Recruitment	✓	[Section]
16a	Sequence generation	✓	[Section]
16b	Allocation	✓	[Section]

	concealment		
16c	Implementation	✓	[Section]
17a	Blinding (who)	✓	[Section]
17b	Unblinding procedures	✓	[Section]
18a	Data collection methods	✓	[Section]
18b	Participant retention	✓	[Section]
19	Data management	✓	[Section]
20a	Statistical methods (outcomes)	✓	[Section]
20b	Statistical methods (subgroups)	✓	[Section]
20c	Statistical methods (missing data)	✓	[Section]
21a	Data monitoring committee	✓	[Section]
21b	Interim analyses	✓	[Section]
22	Harms	✓	[Section]
23	Auditing	✓	[Section]
24	Research ethics approval	✓	[Section]
25	Protocol amendments	✓	[Section]
26a	Consent (model)	✓	[Section]
26b	Consent (ancillary)	✓	[Section]
27	Confidentiality	✓	[Section]
28	Declaration of interests	✓	[Section]
29	Access to data	✓	[Section]
30	Ancillary/post-trial care	✓	[Section]
31a	Dissemination policy (trial)	✓	[Section]
31b	Dissemination policy (authorship)	✓	[Section]
31c	Dissemination policy (reproducibility)	✓	[Section]
32	Informed consent	✓	[Section]

	materials		
33	Biological specimens	✓	[Section]

SPIRIT Compliance: 100% (52/52 items addressed)

PROTOCOL APPROVAL SIGNATURES

Principal Investigator	_____	Date: _____
Department Head	_____	Date: _____
IACUC/IRB Chair	_____	Date: _____